Skip to main content

Table 5 Multivariate analysis in neoadjuvantly treated patients with gastric cancer including AEG II, III (UICC 6th)

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

  

HR

95% CI

p

pT

pT0

1.00

 

0.002

 

pT1

2.16

0.2-20.8

 
 

pT2

5.10

0.7-37.5

 
 

pT3

9.80

1.3-74.3

 
 

pT4

14.50

1.7-122.9

 

R

R0

1.00

 

0.001

 

R1/2

2.20

1.3-3.5

 

Clinical response

yes

1.00

 

0.026

 

no

2.10

1.1-4.2

 

MTHFR A1298C

AA

1.00

 

0.01

 

AC

2.00

1.3-3.2

 
 

CC

1.49

0.7-3.3